Enlarge / The Food and Drug Administration headquarters in White Oak, Maryland.Getty | Congressional Quarterly
The Food and Drug Administration greenlit two updated COVID-19 vaccine booster shots Monday—a day before advisors for the Centers for Disease Control and Prevention are scheduled to meet and vote on recommendations for use of the updated vaccines.
The two shots are the 2023-2024 formulations of mRNA vaccines from Moderna and Pfizer-BioNTech, both of which target the recent omicron subvariant XBB.1.5. The FDA granted full approval of both Pfizer-BioNTech’s updated vaccine (Comirnaty) and Moderna’s updated vaccine (Spikevax) for use in those ages 12 years and
→ Continue reading at Ars Technica